Stay
up-to-date
about
RECOVER
Our understanding of Long COVID is constantly evolving with new research findings. Stay informed by reading the latest news and participating in upcoming events.
This year, RECOVER researchers continue to publish results from research studies that deepen our understanding of Long COVID. RECOVER studies continue, with 2 clinical trials expected to reach enrollment goals this summer.
A recent RECOVER Research Review (R3) Seminar held May 13 spotlighted research presented by Carolyn Bramante, MD, MPH (University of Minnesota) and Steve Johnson, PhD (University of Minnesota) exploring how metformin, a widely prescribed medication primarily used to manage type 2 diabetes, may help reduce the risk of Long COVID. The seminar also featured a presentation from Suzanne Vernon, PhD (Bateman Horne Center) on research examining the risk of developing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) following a COVID-19 infection.
Five RECOVER study sites across the Pacific Northwest teamed up to form a consortium. Consortium members learn from other RECOVER researchers’ findings and share knowledge with the community.
Combining knowledge across different scientific specialties that study biological systems could reveal information that improves the diagnosis of Long COVID and supports the development of personalized Long COVID treatments.
RECOVER researchers studied health records to understand how racial and ethnic backgrounds may impact pediatric Long COVID symptoms. These findings could support early detection and management of Long COVID symptoms for all children.
During the April 8th RECOVER Research Review (R3) Seminar, RECOVER researchers Hannah Mandel, MS, Fei Wang, PhD, Sandy Preiss, MS, and Abhishek Bhatia, MS presented findings from two different studies of electronic health records (EHRs). Rainu Kaushal, MD (Cornell University), Dr. Wang’s co-author, joined the presenters for the panel discussion and audience Q&A. Both studies examined whether taking the antiviral drug Paxlovid during a COVID-19 infection could help prevent Long COVID. Although Paxlovid is known to reduce the risk of severe COVID-19, there has been limited research into how Paxlovid might impact a person’s risk of developing Long COVID. The studies presented are two of the largest to date that have explored the role of Paxlovid in Long COVID prevention.
Patient, Caregiver, and Community Representatives inform RECOVER research, help connect the initiative with different communities, and share news about RECOVER studies.
During the March 11th RECOVER Research Review (R3) Seminar, RECOVER researchers shared findings from a recent study that examined how a person’s sex may affect their risk of developing Long COVID. Dimpy Shah, MD, PhD (University of Texas Health Science Center) presented results from the study, and Nora Singer, MD (Case Western Reserve University, MetroHealth Medical Center) shared background about RECOVER’s adult observational study population and ideas for future research in this area.
During the February 11th RECOVER Research Review (R3) Seminar, Dr. Grace McComsey (Case Western Reserve University) and Dr. Kristine Erlandson (University of Colorado Anschutz Medical Campus) discussed how biomarkers – signs of disease that can be observed and measured – may provide information that will improve researchers’ ability to understand, diagnose, prevent, and treat Long COVID. Dr. McComsey and Dr. Linda Geng (Stanford University) also discussed recent updates to and findings from the RECOVER-Adult Long COVID Research Index.
Media InquiriesAre you a member of the media or press? Please direct inquiries to the RECOVER@nih.gov inbox. Please place "MEDIA INQUIRY" in your subject line.